You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Merck
Mallinckrodt
McKinsey
Moodys
Boehringer Ingelheim
AstraZeneca

Last Updated: September 28, 2020

DrugPatentWatch Database Preview

Patent: 9,354,243

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,354,243
Title:Methodologies and reagents for detecting fibrinolysis and hyperfibrinolysis in a blood sample using viscoelastic analysis
Abstract: In some embodiments, the invention provides methods for detecting fibrinolysis or hyperfibrinolysis in a blood sample from a patient. The method includes subjecting a first portion of a blood sample comprising reduced platelet function to viscoelastic analysis in the absence of an inhibitor of fibrinolysis to obtain a coagulation characteristic of the first portion at a time point; and subjecting a second portion of the blood sample comprising reduced platelet function to viscoelastic analysis in the presence of an inhibitor of fibrinolysis to obtain a coagulation characteristic of the second portion at the time point; wherein a difference between the coagulation characteristic of the first portion and the coagulation characteristic of the second portion indicates fibrinolysis or hyperfibrinolysis in the blood sample.
Inventor(s): Chapman; Michael P. (Denver, CO), Moore; Ernest E. (Denver, CO), Norem; Katherine M. (Rosemont, IL)
Assignee: Haemonetics Corporation (Braintree, MA) The Regents of the University of Colorado, a body corporate (Denver, CO)
Application Number:14/270,269
Patent Claims:see list of patent claims

Details for Patent 9,354,243

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Bayer Hlthcare TRASYLOL aprotinin INJECTABLE;INJECTION 020304 001 1994-02-07   Start Trial Haemonetics Corporation (Braintree, MA) The Regents of the University of Colorado, a body corporate (Denver, CO) 2039-02-26 DISCN search
Centocor Inc REOPRO abciximab INJECTABLE; INJECTION 103575 001 1994-12-22   Start Trial Haemonetics Corporation (Braintree, MA) The Regents of the University of Colorado, a body corporate (Denver, CO) 2039-02-26 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Boehringer Ingelheim
Express Scripts
Moodys
Dow
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.